drugset
drugset / Trial / NCT05008835

Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

NCT05008835 ↗

Phase 2 Terminated 61 enrolled ACADIA Pharmaceuticals Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of ACP-044 compared with placebo in the treatment of pain associated with osteoarthritis of the knee

Timeline

Start
2021-07-20
Primary completion
2022-10-06
Completion
2022-11-16

Outcome

Outcome not reported

Stopped (Business): “Study was terminated for business reasons.”

Drugs

EvaluationDrugModalityDoseRoute
Subject EBARESDAX Small molecule — Oral

Indications

osteoarthritis, knee